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Abstract
Background: Fucosidosis results from lack of α-L-fucosidase activity, with accumulation of fucose-linked substrates
in the nervous system and viscera leading to progressive motor and mental deterioration, and death. The naturally
occurring dog model of fucosidosis was used to evaluate the neuropathological responses to partial enzyme
replacement, and substrate reduction in early disease following treatment with recombinant canine α-L-fucosidase
delivered through cerebrospinal fluid.
Methods: Neuropathology in both treated (n = 3) and untreated fucosidosis-affected (n = 3) animals was evaluated
with immunohistochemistry, image analysis, manual quantification and gene expression analysis and compared
with unaffected age-matched controls (n = 3) in an extension of our previous biochemical report on the same
cohort. Data were analyzed by ANOVA.
Results: Quantification demonstrated a consistent trend to reduction in vacuolation, pyramidal neuron loss,
astrocytosis, microgliosis, perivascular storage, apoptosis, oligodendrocyte loss, and hypomyelination throughout the
central nervous system of enzyme treated animals compared to placebo-treated, age-matched affected controls. Key
lesions including lysosomal expansion in neurons of deep cortex, astrocytosis in cerebral cortex and medulla, and
increased lysosomal membrane associated protein-1 (LAMP-1) gene expression were ameliorated in treated animals.
There was no change in spheroid formation and loss of Purkinje cells, but Purkinje cell vulnerability to apoptosis was
reduced with treatment.
Conclusions: Despite reduced severity of fucosidosis neuropathology with partial enzyme replacement, more
complete and sustained biochemical correction is required to halt neuropathological processes in this large animal
model of lysosomal storage disease.
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Background
Canine fucosidosis is an animal model for the homolo-
gous human lysosomal storage disorder (LSD) resulting
from the loss of functional α-L-fucosidase enzyme
activity. It is the only preserved animal model of fucosi-
dosis (OMIM#23000), and has been invaluable in test-
ing treatment strategies, such as haematopoietic cell
transplantation (HCT) [1]. Characteristic features of
fucosidosis neuropathology including with accumula-
tion of fucosyl glycoasparagines, lysosomal expansion,
hypomyelination, gliosis, neuronal loss, axonal dys-
trophy and apoptosis are present in the canine model
by 8 weeks of age; 8–10 months before the onset of
motor and mental deficits [2, 3]. Consistent signs of
ataxia, hypermetria and behavioral changes commence
at 12–18 months and at this stage, there is widespread
vacuolation in neurons and glia across the brain, and a
16 % decrease in myelin density accompanied by an
average 38 and 54 % loss of oligodendrocytes in the
cerebellum and corpus callosum [2, 4]. By 24 months,
affected animals demonstrate severe gait deficits, spon-
taneous nystagmus and loss of menace response, with
an average of 76 % fewer Purkinje cells and 59 % fewer
pyramidal neurons compared to normal age-matched
adults [3].
In canine fucosidosis, HCT increased α-L-fucosidase
activity to more than 10 % of normal in the nervous
system 6 months after engraftment, ameliorated neuro-
pathological lesions and there was a substantial, life-long
reduction in clinical signs [1, 5, 6]. HCT is an option for
fucosidosis-affected infants if diagnosed soon after birth,
but requires a compatible donor and entails substantial
risks with limited benefit in severe disease or in late-
onset cases [7, 8]. There is a compelling need for a safe
and successful treatment for fucosidosis, which due to
the neurologic involvement requires the delivery of
therapeutic agents across the blood-brain barrier. This
may be achieved by direct delivery of replacement
enzyme into the cerebrospinal fluid (CSF) via intrathecal
or intracisternal infusion. In canine fucosidosis, low-
dose, monthly intracisternal enzyme replacement ther-
apy (ERT), increased enzyme activity by 2–72 % in the
spinal cord and most areas of the brain [9]. Accompany-
ing substrate reduction ranged from 0 to 80 % [9].
More consistent reduction in biochemical measures of
storage ranging from 12 to 73 % was achieved in LSD
models murine mucopolysaccharidosis (MPS) IIIA and
canine MPS I, where high dose, frequent and sustained
intra-CSF ERT was employed [10–13]. A milder neuro-
logic phenotype is observed in these MPS models com-
pared to canine fucosidosis, and MPS I dogs receiving
monthly and quarterly intrathecal infusions also received
ERT intravenously [13]. In MPS IIIA mice, greater
substrate reduction was achieved in the midbrain and
cerebellum, close to the cerebromedullary infusion site
[11]. The response of brain lesions to ERT in MPS IIIA
mice was variable. Immunohistochemical markers of
substrate accumulation demonstrated reductions, but
inflammatory lesions and axonal dystrophy persisted in
the inferior colliculus, hippocampus and thalamus [11].
Lysosomal expansion, axonal spheroids, hypomyelina-
tion, increased apoptosis and gliosis all require repair in
fucosidosis, and the neuropathological response to low-
dose, monthly intracisternal infusion of same-species
recombinant enzyme in canine fucosidosis has yet to be
reported.
In this study, we further evaluated the efficacy of re-
duced substrate storage after intra-CSF delivery of canine
α-L-fucosidase in our previously reported cohort [9], using
quantitative techniques to evaluate neuroinflammatory,
myelin, lysosomal and neuronal pathology in preclinical
fucosidosis.
Methods
Intracisternal injection experiments and sample collection
Monthly intracisternal infusions of recombinant canine α-
L-fucosidase were administered in fucosidosis-affected
English Springer spaniel pups (n = 3, affected enzyme
treated (AET) 1, AET2, AET3) from 8 weeks of age for
3 months. Phosphate buffered saline (PBS) vehicle infu-
sions were performed in age-matched fucosidosis-affected
controls (n = 3, affected vehicle treated (AVT)1, AVT2,
AVT3) and unaffected controls (n = 3, control vehicle
treated (CVT)1, CVT2, CVT3). Biochemical data from
this cohort of dogs is reported in [9], where detailed
description of the intracisternal infusion procedure, and
manufacture of replacement enzyme can be found. Briefly,
6.9U (0.96 mg/dose) of enzyme in 150–204 μL of PBS
for AET dogs or 150 μL PBS vehicle for AVT and CVT
animals was slowly infused via cisternomedullary CSF
cannula under anesthesia over a period of 2 min. Dog
AVT2 was euthanized at 12 weeks following an adverse
anesthetic response. The remaining dogs were euthanized
at 16 weeks, 48 h after the third infusion with an intraven-
ous overdose of phenobarbital sodium at 150 mg/kg.
Neural tissues were collected for gene expression and
histological analysis. All procedures were approved by the
Animal Ethics Committee at Westmead Hospital, The
University of Sydney and followed the Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes.
Histology and immunohistochemistry
Superficial frontal cortex (0.2 mm depth from the men-
ingeal surface), deep frontal cortex (2–4 mm depth),
corpus callosum, striatum, medulla, molecular layer of
the cerebellum, cerebellar nuclei and cervical spinal cord
were fixed in 10 % neutral buffered formalin for paraffin,
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or 2.5 % glutaraldehyde for epoxy resin embedding.
Paraffin embedded sections were cut at 5 μm and placed
on plain or silane coated slides prior to histochemical or
immunohistochemical staining. Resin semi-thin sections
were cut at 0.5–1 μm thickness and stained with 1 %
toluidine blue. Histochemical stains luxol fast blue
with periodic acidic Schiff (LFB/PAS) and haematoxylin
and eosin (H&E). Immunohistochemical staining using
glial fibrillary acid protein for astrocytes (GFAP, 1:2000,
polyclonal rabbit anti-GFAP, Dako, Glostrup, Denmark),
ubiquitin for axonal spheroids (1:4000, polyclonal rabbit
anti-ubiquitin, Dako), and Ricinus communis agglutinin-
1 lectin for microglia (RCA-1, 1:2500, biotinylated, Vec-
tor Laboratories, Burlingame, CA, USA) were performed
as described in [3]. Caspase-6 for apoptosis (CASP6,
1:2000, polyclonal rabbit anti-CASP6, Abcam, Cambridge,
UK) and 2’,3’-cyclic-nucleotide 3’-phosphodiesterase for
terminal differentiating mature oligodendrocytes (CNPase,
1:400, monoclonal mouse anti-CNPase, Millipore, Temec-
ula, CA, USA) was performed as described in [4]. All im-
munostaining was visualized using 3,3’-diamenobenzidine
substrate and counterstained in hematoxylin.
Quantitative assessment of neuropathology
All quantification was undertaken with observers blind
to the identity of the sample. Matched regions were
quantified from each dog as follows: lateral lobe of
frontal cortex superficial layers 1–4, and deep layers 5
and 6, corpus callosum, striatum (globus pallidus), thal-
amus, medulla and cervical spinal cord.
Astrocytosis, microgliosis, hypomyelination and vacuolation
A consistent block design was used to select 15 fields in
the defined neuroanatomical regions using the Leica
Q500MC image processing and analysis system (Leica
Cambridge Ltd, Cambridge, UK).
To quantify ‘astrocytosis’, ‘microgliosis’, and ‘myelin
loss’ the percentage of positive staining for GFAP, RCA-
1 and LFB/PAS (blue) tissue respectively, was averaged
from 15 high-power fields as described previously [2, 3].
‘Vacuolation’ or the percentage of area vacuolated was
determined by measuring the area occupied by H&E
stain and subtracting the total area to give the transpar-
ent unstained area, as described in [2].
Photomicrographs of GFAP, H&E, LFB/PAS and RCA-
1 stained sections were captured using a digital camera
(Olympus DP-70, Olympus Australia Ltd, Sydney,
Australia) attached to a light microscope (Olympus
BX-51, Olympus Australia Ltd).
CASP6 apoptosis and oligodendrocyte counts
CASP6 staining and CNPase positive oligodendrocyte
counts were quantitatively assessed in photomicrographs
captured using a digital camera (Olympus DP-70, Olympus
Australia Ltd) attached to a light microscope (Olympus
BX-51, Olympus Australia Ltd) and functions available in
ImageJ (National Institutes of Health, USA). Percentage of
CASP6 staining in the cerebellar white matter and corpus
callosum was measured in 10–15 fields of view captured at
400× magnification using the automated threshold function
following pre-processing to the hue, saturation and bright-
ness color space. To assess the number of mature oligo-
dendrocytes, manual counts using the ‘cell count’ tool
were performed on 10–15 fields of view of the corpus
callosum and cerebellar white matter captured at 1000×
magnification. Oligodendrocytes were identified as cell
nuclei with CNPase positive cytoplasmic staining.
Counts were expressed as total number of oligodendro-
cytes per mm2 cerebral or cerebellar white matter.
Manual counts of CASP6 positive Purkinje cells were
performed on 15 fields of view captured at 400× magni-
fication. The total number of Purkinje cells and the
number of CASP6 positive Purkinje cells at the border
of the molecular and granule cell layers were counted.
Counts were expressed as the percentage of positive
CASP6 Purkinje cells per 1000 μm length of the border.
The absence or presence of vacuolation and degenerate
Purkinje cells with baskets were also noted.
Pyramidal neuron counts, perivascular spaces and
lysosomal expansion within neurons
Pyramidal neuron counts and measurement of perivascu-
lar spaces were performed as described in [3]. For both
measurements, images were collected at high power. The
number of pyramidal neurons present in the fusiform
layer of the frontal cerebral cortex were counted and
expressed per 100000 μm2. Perivascular space measure-
ments corresponding to the Virchow-Robins space were
taken at peri-arteriole and peri-venule regions within the
parenchyma of the dorsal frontal cortex, within 1–2 cm of
the mid-sagittal sulcus. The average perivascular space
was measured by determining the width of the space
between the endothelial membrane and the adjacent par-
enchyma. A minimum of 15 perivascular spaces were
measured per dog.
To assess the lysosomal expansion within neurons ‘vac-
uoles per neuron’ were counted in photomicrographs of
semi-thin resin sections of the superficial (layers 1–4) and
deep (layers 5 and 6) frontal cortex captured at 1000×
magnification. In each neuroanatomically defined region,
15 complete neurons (distinct cytoplasm and nucleus)
were identified, and the number of membrane-bound vesi-
cles identified as putative lysosomes within neuronal cyto-
plasm were manually counted and averaged. Criteria for
positively identifying neurons were large nucleus, clumped
chromatin, large nucleoli, cytoplasm with Nissl substance
(ribosomes, rough endoplasmic reticulum), distinctive
axonal processes and adjacent supporting glia.
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Gene expression of neuroinflammatory and lysosomal
membrane protein markers
To assess the value of proinflammatory cytokines and
lysosomal membrane proteins as markers of reduced stor-
age and secondary inflammation following treatment,
relative expression of interleukin (IL)-6 and −8, trans-
forming growth factor-β (TGFβ) and lysosomal mem-
brane associated protein-I (LAMP1) was determined
using quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR). Following necropsy, the lat-
eral lobe of the frontal cerebral cortex from each of the
AET, AVT and CVT dogs was snap frozen in liquid
nitrogen at necropsy prior to RNA extraction (RNeasy
Lipid Tissue Mini kit, QIAGEN, MD, USA). cDNA was
synthesized from 2 μg of total RNA using reverse tran-
scriptase (SuperScript III, Life Technologies, CA, USA)
and oligo(dT) primer (Life Technologies). PCR primers
(Additional file 1) were derived from the literature
(GAPDH [14]) or designed from canine-specific cDNA
sequences (GenBank/EMBL data bank, CanFam 2.0
May 2005 annotation) using Primer3 [15]. Primer
stocks were diluted to a working concentration of
100 ng/μL. All primers were tested for PCR functional-
ity by running reaction products on 2 % agarose gels in
tris-acetate-EDTA.
qRT-PCR was performed in triplicate 20 μL reactions
using a Rotor-Gene 6000 (QIAGEN) under the following
conditions: initial denaturation at 95 °C for 5 min,
followed by 35 cycles of 95 °C for 30 s, 60 °C for 30 s,
72 °C for 30 s in the presence of 3 mM MgCl2 and
0.8 μL of 1X SYBR® Green I (Molecular Probes, Eugene,
OR, USA). A melt run was performed at 72–95 °C to
confirm a single product. Relative gene expression of
was performed by normalizing to GAPDH, as an internal
standard.
Statistical analysis and data representation
Significant differences between groups were determined
by ANOVA (GenStat 11th Edition, VSN International
Ltd, Hertfordshire, UK). All data were analyzed using
logit transformation due to unequal variances. p < 0.05
was regarded as significant, p < 0.001 as highly signifi-
cant. As AVT2 was 12 weeks, and AVT1 and 3 were
16 weeks at necropsy data were analyzed with and
without AVT2 and differences noted in results.
A correction index (CI) was developed as a measure of
the extent of correction achieved by ERT in AET animals
relative to AVT controls for vacuolation, substrate and
additional neurodegenerative markers. CI was calculated
as the mean measure in the AVT group minus the mean
measure in the AET group divided by the mean measure
in the AVT group, eg. in Fig. 1a (9.38–7.17)/9.38 = 0.24 CI.
A large absolute value close to 1 indicates a large change
in that maker in AET animals compared to AVT controls.
Results
All dogs tolerated the infusion procedure well, and there
was no histological evidence of reactive meningitis in
either of the infusion vehicle treated AVT and CVT
dogs, or the AET recombinant canine α-L-fucosidase
treated animals. Fucosidosis lesions including vacuol-
ation (lysosomal expansion), hypomyelination, astrocyto-
sis, microgliosis and neuron loss were ameliorated to
varying degrees in AET brain. There were small, consist-
ent reductions in vacuolation as indicated by the CI
across forebrain regions of AET animals compared to
AVT controls (Table 1). This included the corpus callo-
sum, striatum and thalamus. Small reductions in vacuol-
ation were also observed in hindbrain regions and spinal
cord (Table 1). Axonal spheroid formation in AET ani-
mals remained unchanged in all regions of the brain.
Frontal cerebral cortex
Lysosomal expansion in superficial and deep cerebral cortex
Mean vacuolation in AET dogs was significantly reduced
in cortical layers 5 and 6 compared to untreated AVT
animals (Fig. 1a), in which spongy vacuolation of the
deep cortical parenchyma is prominent. In cortical layers
1–4, there was no significant change in the percentage
of vacuolation with administration of intracisternal ERT
(Fig. 1c). However, quantitative assessment of lysosomal
expansion within neurons using ultrastructual examin-
ation demonstrated a significant decrease in the number
of ‘vacuoles per neuron’ in the superficial cortex (0.18 CI)
of AET dogs (Fig. 1b). There was no significant change
(0.21 CI) in ‘vacuoles per neuron’ identified between AET
and AVT dogs in cortical layers 5 and 6, where despite
reduction in overall mean vacuolation, degenerative
changes to neurons persisted. These included cytoplasmic
distortion, disintegrated Nissl substance and chromatin
condensation (Fig. 2b).
Perivascular regions
Measurement of Virchow-Robins spaces within the pyr-
amidal neuronal layer of the frontal cortex revealed that
their thickeness in AET brain were significantly reduced
compared to AVT dogs, ranging from 0.12 to 0.16 μm,
similar to the mean of 0.14 μm observed in unaffected
controls (0.39, Fig. 1e). Accumulation of vacuolated
microglia and macrophages around vascular regions caus-
ing distention of perivascular spaces was prevalent in
AVT frontal cortex.
Hypomyelination
Following intracisternal ERT, the number of oligoden-
drocytes per mm2 in the corpus callosum was sig-
nificantly preserved compared to untreated AVT dogs
(Table 2, Fig. 4a-c). Despite this, there was no significant
change in the density of cortical white matter tracts
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observed with LFB/PAS staining in AET dogs compared
to AVT (0.07CI, Fig. 1f ).
Astrocytosis and microgliosis
Following intracisternal ERT, astrocytic processes ap-
peared reduced in length (Fig. 2p–r), and in the cerebral
cortex GFAP staining was significantly reduced in AET
dogs (0.16 CI, Fig. 1g). There was no change in thalamic
astrocytosis following enzyme infusion (AET: 36.6 %,
AVT: 36.9 %, 0.008 CI).
In the frontal cerebral cortex, there was a trend to-
wards reduced microgliosis in AET animals (0.35CI,
Fig. 1h) with fewer RCA-1 lectin positive microglia
(Fig. 2m–o). In both AET and AVT animals, activated
microglia and macrophages were localized adjacent to
intense neuronal and endothelial vacuolation.
Fig. 1 Quantification of neurodegenerative and inflammatory markers in frontal cerebral cortex following intracisternal enzyme infusion.
Quantification of (a) area vacuolation in deep frontal cerebral cortex, (b) ‘vacuoles per neuron’ in deep frontal cerebral cortex, (c) vacuolation in
superificial frontal cerebral cortex, (d) ‘vacuoles per neuron’ in deep frontal cerebral cortex, (e) average thickness of perivascular space in frontal
cerebral cortex, (f) LFB/PAS staining in deep white matter tracts of frontal cerebral cortex following enzyme infusion, (g) area GFAP staining in
frontal cerebral cortex, (h) area RCA-1 lectin staining in frontal cerebral cortex. Different letters (a, b, c) indicate significant difference between
groups at p < 0.05
Table 1 Percentage of vacuolation and CI of deep regions of
cerebrum
Region CVT (n = 3) AET (n = 3) AVT (n = 3) CI
Corpus callosum 0.55 ± 0.1 a 5.78 ± 1.1 b 6.66 ± 1.4 b 0.13
Striatum 0.31 ± 0.1 a 2.65 ± 1.0 b 3.52 ± 1.3 b 0.25
Thalamus 0.34 ± 0.1 a 3.07 ± 0.9 b 4.03 ± 1.3 b 0.23
Medulla 0.78 ± 0.25 a 7.65 ± 2.4 b 7.68 ± 2.2 b 0.03
Spinal cord 4.63 ± 1.5 a 10.78 ± 3.5 b 12.79 ± 4.1 b 0.16
Mean ± SEM. a,b different letters indicate significant difference between
affected dogs and unaffected controls at p < 0.05
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Axonal spheroids, pyramidal neuron loss and apoptosis
Axonal spheroid formation in the corpus callosum
(Fig. 2j–l) did not change with enzyme infusion (Fig. 3a). Pyr-
amidal neuron loss was less severe in AET frontal cerebral
cortex compared to AVT, but there was no significant
improvement (0.22 CI, Fig. 3b). CASP6 staining remained
elevated in AET corpus callosum compared with CVT
controls, with no effect of intracisternal ERT (Fig. 4d–f ).
Fig. 2 Histology and immunostaining in the frontal cerebral cortex of CVT, AET and AVT dogs. a–c H&E sections of CVT, AET and AVT showing
vacuolation, (d) toluidine blue section of AET showing vacuoles in different cell types, (e–g) ubiquitin immunostaining, (h–j) LFB/PAS staining of
deep white matter tracts of frontal cerebral cortex, (k-m) RCA-1 lectin (k-m) and GFAP (n–p) immunostaining staining in frontal cerebral cortex of
CVT, AET and AVT. indicate vacuolation, putative microglia with numerous membrane bound vesicles, membrane bound vesicles in neuron,
indicate enlarged perivascular space, indicate LFB staining, indicate ubiqutin positive deposits, indicate lectin (RCA-1) staining and indicate GFAP
stained astrocytes. Inserts are at 1000× magnification
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Fig. 3 Quantification of neurodegenerative and inflammatory markers in CNS following intracisternal enzyme infusion. Quantification of (a) area
of ubiquitin staining in frontal cerebral cortex, (b) pyramidal neurons in frontal cerebral cortex, (c) area vacuolation and, (d) area of GFAP staining
in medulla, (e) area vacuolation in cervical spinal cord grey matter. Expression levels of (f) LAMP-1, (g) TGF-β, (h) IL-6 and (i) IL-8 genes in superfi-
cial frontal cerebral cortex. Different letters (a, b, c) indicate significant difference between groups at p < 0.05
Table 2 The effect of intracisternal ERT on measures of oligodendrocyte loss and apoptosis
Measure CVT (n = 3) AET (n = 3) AVT(n = 3) CI
Oligodendrocytes per mm2 white matter
Cerebellar white matter 907 ± 66 a 584 ± 66 b 521 ± 66 b −0.12
Corpus callosum 1366 ± 60 a 889 ± 60 b 603 ± 60 c −0.47
Percentage of CASP6 staining
Cerebellar white matter 1.2 ± 0.5 % 1.3 ± 0.5 % 2.0 ± 0.8 % 0.35
Corpus callosum’ 0.5 ± 0.2 % a 5.0 ± 1.9 % b 5.5 ± 2.2 % b 0.09
Purkinje cells 20.9 ± 7.2 % a 49.2 ± 7.2 % b c 77.7 ± 7.2 % c 0.37
Mean ± SEM. a,b,c different letters indicate significant difference at p < 0.05
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Cerebellum
Vacuolation, astrocytosis and hypomyelination demon-
strated minor reductions in the cerebellum following intra-
cisternal ERT, but these did not reach significance. Lower
levels of CASP6 staining was present in the cerebellar white
matter of AET dogs compared to AVT (0.35 CI), but
cerebellar oligodendrocyte numbers remained unchanged
despite intracisternal ERT (Table 2).
The number of Purkinje cells positive for apoptosis
vulnerability marker CASP6 were significantly decreased
in AET compared to AVT (0.37 CI), but remained elevated
compared to CVT animals (Table 2, Fig. 4g–i). All
CASP6-positive Purkinje cells in AET and AVT animals
demonstrated vacuolation, and the occasional degenerate
empty basket, as well as CASP6-positive Bergmann glia
were present (Fig. 4g–i). There was no difference in the
Fig. 4 Oligodendrocytes and apoptosis in the corpus callosum and cerebellum following intracisternal enzyme infusion. CNPase immunostaining
in the corpus callosum (a–c) and CASP6 immunostaining in the corpus callosum (d–f) and cerebellum (g–i) of CVT, AET and AVT. Δ indicates
CNPase positive oligodendrocytes. Inserts (d–f) are at 1000× magnification (arrowheads)
Table 3 Neurodegenerative markers in cerebellum following enzyme replacement therapy
Neurodegenerative markers in cerebellum CVT (n = 3) AET (n = 3) AVT (n = 2–3) CI
Vacuolation in molecular layer 0.26 ± 0.0 a 5.47 ± 1.1 b 5.52 ± 1.2 b 0.09
Vacuolation in cerebellar nuclei 0.52 ± 0.2 a 3.38 ± 1.6 b 4.87 ± 2.3 b 0.30
Purkinje cell counts 12 ± 0.8 a 10 ± 0.5 b 10 ± 0.2 b 0.00
Myelination 67.18 ± 0.8 a 58.00 ± 3.2 b 55.02 ± 2.3 b 0.05
Astrocytosis 6.77 ± 0.4 a 13.05 ± 0.8 b 14.24 ± 0.9 b 0.08
Axonal spheroids 0.01 ± 0.5 a 0.84 ± 0.6 b 0.84 ± 0.0* b 0.00
Mean ± SEM. a,b different letters indicate significant difference between affected dogs and unaffected controls at p < 0.05
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total number of Purkinje cells observed between AET and
AVT (Table 3).
Axonal spheroids present in the cerebellar white matter
did not response to enzyme infusion (Table 3).
Medulla and spinal cord
The percentage of vacuolation in the medulla was un-
changed by intracisternal ERT (Fig. 3c). Enzyme infusion
led to a small but highly significant reduction in GFAP
staining in AET medulla (0.13 CI, Fig. 3d). In the cervical
spinal cord there was a trend towards reduced vacuolation
(0.16 CI, Fig. 3e).
LAMP-1 and inflammatory gene expression in fucosidosis
brain following ERT
Gene expression (Fig. 3f–i) demonstrated positive re-
sponses to therapy. LAMP-1 expression in the superficial
frontal cortex was significantly reduced following enzyme
infusion (0.57 CI, Fig. 3f). TGFβ gene expression showed
decreases with intracisternal ERT (0.44 CI, Fig. 3g) and
both IL6 and IL8 demonstrated a trend towards reduction
in AET cerebral cortex compared to AVT (0.39 CI, Fig. 3i).
Discussion
This study provides clear evidence of differential cor-
rective effects in brain and spinal cord following intra-
cisternal delivery of replacement enzyme in LSD with
severe neurological involvement. It is the first study to
identify relationships between reduced storage measured
by vacuolation, and a broad range of other neurodegener-
ative lesions following partial enzyme replacement and
substrate correction in fucosidosis. Administration of
species-matched recombinant enzyme was safe, and well-
tolerated by the dogs in this study, with no histological
evidence of reactive meningitis to either PBS infusion
vehicle or the treatment enzyme following repeated injec-
tion. This was supported by previous findings of normal
cellularity and protein levels in CSF, and no antibody re-
sponse to the recombinant enzyme or infusion vehicle for
all treatment groups [9]. Despite persistence of small
vacuoles in endothelial cells at the ultrastructural level,
decreases in the perivascular accumulation of macro-
phages in the cortex was the most responsive marker to
treatment, and is consistent with perivascular uptake of
enzyme infused via CSF [16]. The small reductions in
measures of vacuolation, astrocytosis, microgliosis, ‘vacu-
oles per neuron’, pyramidal neuron counts and hypomyeli-
nation in fucosidosis-affected cerebral cortex, cerebellum,
medulla and spinal cord are consistent with studies in
MPS I and IIIA dogs, which have demonstrated that these
regions are responsive to biochemical correction [10, 17].
Axonal dystrophy and Purkinje cell loss showed no
response, but reductions in the number of CASP6-
positive Purkinje cells suggest that rescue of Purkinje
neurons by intracisternal ERT may be seen over time with
continued treatment.
Infusion of enzyme via CSF contrasts with HCT, where
enzyme is delivered by myeloid derived donor cells mi-
grating diffusely from circulation to populate the brain
throughout life, forming at least 10 % of all ‘resident’
microglia [18]. Monthly intracisternal infusions provide
a transient source of replacement enzyme, and this likely
contributed to the subtle and variable effects observed in
intracisternal-ERT treated animals. Measures strongly
associated with substrate accumulation including cerebro-
cortical vacuolation, ‘vacuoles per neuron’, perivascular
accumulation and LAMP-1 gene expression demonstrated
significant reductions in fucosidosis dogs treated with
intracisternal ERT. This aligns with the moderate and
consistent biochemical correction achieved in the same
cohort of animals. Levels of fucosylated oligosaccharide
were reduced by 23–80 % in all regions of the CNS
sampled, except the thalamus and corpus callosum [9].
Secondary lesions, other than cortical astrocytosis, were
refractory to this regime of intracisternal ERT although
there was a trend towards reduced disease burden across
all CNS regions sampled. In the future, an increased co-
hort of animals, or additional markers including fucose-
specific lectins [19], or immunohistochemistry against the
recombinant infusion enzyme may enable more precise
evaluation of the distribution and regional effects of the
ERT infusion.
The variability in the region and the extent of neuro-
pathological improvement likely relates to both the pattern
of enzyme absorption from the CSF into the parenchyma
of the brain, and the severity of pre-existing lesions. Studies
in canine MPS IIIA demonstrate that ERT delivered via
CSF follows perivascular spaces, with subsequent centrifu-
gal spread to neurons, astrocytes and oligodendroglia [16].
This was determined using immunohistochemistry against
recombinant N-sulfoglucosamine sulfohydrolase used in
these ERT studies [16]. The significant reduction in the
thickness of Virchow-Robins spaces with intracisternal-
ERT treated in fucosidosis dogs towards that seen in
unaffected controls, supports this. However, lesions in the
cerebellum, the structure closest to the infusion site of
the cisterna magna, demonstrated a poor response to
therapy. This is difficult to reconcile, as the cerebellum
had high levels of enzyme activity 48 h after the final
infusion (25–36 %) and demonstrated 23–45 % reduc-
tion in oligosaccharide accumulation [9].
High enzyme activity in the cerebellum is consistent
with studies of CSF dispersal following intracisternal infu-
sion in canines, where the pulsating flow of CSF through
the subarachnoid space of the CNS initially drives infu-
sions rostrally towards the cerebrum and caudally towards
the cervical spinal cord, allowing diffusion into the cere-
bellum [20]. However, poor neuropathological responses
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to therapy in the cerebellum have also been identified in
MPS I and IIIB dogs receiving enzyme replacement
through gene therapy. Again, this is a treatment method
that provides long-lasting enzyme replacement, and in
these animals significant levels of correction in cortical
and thalamic vacuolation were achieved, without correc-
tion of lysosomal expansion in the cerebellum [17]. It is
possible that despite the 23–45 % biochemical reduction
in oligosaccharide achieved in the cerebellum by α-L-
fucosidase infusion, pre-existing lesions were unable to be
reversed, and this is reflected in the slight reductions
observed in cerebellar vacuolation and astrocytosis.
Despite this, infusion of α-L-fucosidase slowed the
continued development of neurodegenerative lesions, in-
cluding secondary neuroinflammatory changes. Cerebro-
cortical astrocytosis demonstrated a significant response
to intracisternal ERT, and cortical upregulation of cyto-
kine genes, and RCA-1 lectin stained microgliosis in
showed subtle reductions. Expression of IL6 and IL8
genes were also reduced with treatment and these cyto-
kines may have potential as markers of storage-induced
inflammation which may be monitored in blood or CSF.
Additional inflammatory genes including major histo-
compability class II, chemokine C-C motif receptor-1
and 5, cathepsin S and IL1A are upregulated in preclin-
ical fucosidosis frontal cortex [21] and may also be suit-
able candidates for monitoring responses to therapy in
the future.
Although, the 6.9U monthly dose for 3 months was in-
sufficient to halt the inflammatory changes in canine
fucosidosis, minimizing the extent of neuroinflammation
may be integral to providing a beneficial clinical out-
come. Chronic neuroinflammation is known to mediate
apoptosis [22], the ultimate cause of clinical dysfunction.
Mild and regionally variable reductions in inflammatory
pathology in fucosidosis following intracisternal ERT are
consistent with findings of regional variable reductions
of lectin-stained microglia in MPS IIIA mice, which
received ERT via CSF [11]. The decreasing inflammatory
responses observed with reductions in cerebrocortical
astrocytosis and microgliosis in fucosidosis is likely a
downstream effect of reduced substrate accumulation
and lysosomal expansion demonstrated in layers 5 and
6. It also corresponded with significantly reduced
LAMP-1 gene expression, which as with other lysosomal
membrane proteins is a sensitive marker of lysosomal
system expansion in LSD [10, 11].
Axonal dystrophy (spheroids) was resistant to intra-
cisternal ERT in fucosidosis, as it has been resistant to
intracisternal ERT in MPS IIIA mice [11], and early
haematopoietic chimerism and reversal of substrate accu-
mulation in ovine and bovine α-mannosidosis [23, 24].
The development of axonal dystrophy coincided with the
period of treatment since axonal spheroids were rare in
the cortex and cerebellum at 8 weeks in canine fucosidosis
[3], and widespread by 16 weeks. This indicates that
partial enzyme replacement is insufficient to arrest the
abnormality in axonal transport. Some reduction of axonal
spheroids were observed in the frontal cortex of α-
mannosidosis cats treated with HSCT at 10 and 12 weeks
of age compared to 9 week old untreated [25], but overall
axonal dystrophy appears to be resistant to all enzyme
targeted therapies for LSD.
In contrast, myelin abnormalities (both demyelination
and hypomyelination) demonstrate positive responses to
enzyme target therapies in LSD, although reductions in
fucosidosis hypomyelination were mild in the current
study. Genes encoding myelin-specific proteins 2’,3’-cyc-
lic nucleotide 3’-phosphodiesterase (CNP), oligodendro-
cyte myelin paranodal inner loop protein (OPALIN),
myelin-associated glycoprotein (MAG), and myelin and
lymphocyte (MAL) were significantly downregulated in
preclinical fucosidosis-affected cortex [21], consistent
with a 56 % loss of oligodendrocytes [4] and the decline
in the density of LFB/PAS stained tracts. Hypomyelina-
tion was slightly ameliorated following intracisternal
ERT in preclinical fucosidosis-affected dogs, and there
was a 21 % increase in the survival of oligodendrocytes
at 16 weeks of age. An improvement in brain myelin-
ation detected by magnetic resonance imaging (MRI)
was reported in α-mannosidosis cats following gene
therapy [26]. Hypomyelination was found to be im-
proved in human fucosidosis HCT in MRI studies [7, 8],
with a 4 year follow up showing that the treated child
reached age appropriate levels of myelination [7]. Preser-
vation of callosal oligodendrocytes in canine fucosidosis
treated with intracisternal ERT supports the idea that
the initial hypomyelinating deficits in this LSD are
amenable to enzyme targeted therapy, and in the future
monitoring myelin response to treatment by MRI may
be a reliable and less invasive marker of improved brain
environment and improved clinical outcomes.
The impact of therapy on neuronal survival and func-
tion is of the highest importance in averting irreversible
mental retardation in LSD, but few studies have addressed
the regional differences in neuron loss, the relationship to
apoptosis or responsiveness to therapy. Neuron loss is
widespread and progressive in canine fucosidosis with
0.9–1.2-fold decrease in cerebrocortical and cerebellar
Purkinje neuron numbers, and increased apoptosis
(deoxynucleotide transferase mediated dUTP nick-end
labeling) at 16 weeks of age in both regions [3]. Early
intracisternal ERT had a beneficial effect, reducing
lysosomal expansion and neuron loss in the frontal
cortex with significant decrease in the number of
putative enlarged lysosomes within neurons and a
trend towards reduced pyramidal neuronal loss. There
were also positive reductions in cortical apoptosis
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with significantly fewer cells positive for CASP6, a
marker of vulnerability to apoptosis.
The effect of intracisternal ERT on cerebellar neurons
was less pronounced, with only a trend towards reduced
apoptosis vulnerability in cerebellar white matter and no
difference in total number of Purkinje cells present in
treated and untreated fucosidosis cerebellum. This was
despite a significant decrease in the number of Purkinje
cells positive for CASP6. Reduced vulnerability to apop-
tosis likely does not translate to reduced Purkinje cell
loss immediately, and the apparent regional difference in
neuronal treatment response may relate to different
levels of susceptibility in neuronal subpopulations to
substrate accumulation. Continuation of this low-dose
ERT regime in fucosidosis may be insufficient to prevent
development of the cerebellar signs of ataxia, hyperme-
tria and proprioceptive deficits which commence at
10–12 months of age. However, the increased survival of
cortical pyramidal neurons with this treatment is prom-
ising, providing encouragement that ERT, like HCT, may
delay the progressive cortical dysfunction if adequate
enzyme levels are sustained from early life.
Conclusions
Intracisternal ERT with species-matched recombinant
enzyme was safe with no signs of reactive meningitis, and
there were significant improvements in deep cerebrocorti-
cal vacuolation, superficial cortex ‘vacuole per neuron’,
cortical astrocytosis, and cortical LAMP-1 gene expres-
sion in the fucosidosis CNS as a result of treatment. A
consistent, albeit small response to treatment in other
measures such as myelination, microgliosis and cortical
neuron loss was established through quantification. Re-
duction of storage material in perivascular macrophages
was the most responsive measure, consistent with greater
exposure of perivascular regions to fluctuations in CSF-
delivered enzyme activity. Trends towards improvement
in almost all measures of neurodegeneration and inflam-
mation in the frontal cortex, cerebellum, medullar and
spinal cord provide promise that more intensive ERT
would improve treatment outcomes. The importance of
sufficient, sustained, very early treatment, before lesions
establish and cause irreversible damage and clinical signs
cannot be overstated in fucosidosis, and other lysosomal
disease.
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